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Opinion statement
Autoimmune neuromuscular disorders in childhood include Guillain-Barré syndrome and its
variants,chronicinflammatorydemyelinatingpolyradiculoneuropathy(CIDP),juvenilemyas-
thenia gravis (JMG), and juvenile dermatomyositis (JDM), along with other disorders rarely
seen in childhood. In general, these diseases have not been studied as extensively as they
havebeeninadults.Thus,treatmentprotocolsforthesediseasesinpediatricsareoftenbased
on adult practice, but despite the similarities in disease processes, the most widely used
treatmentshavedifferenteffectsinchildren.Forexample,someofthesideeffectsofchronic
steroiduse,includinglineargrowthdeceleration,bonedemineralization,andchronicweight
issues, are more consequential in children than in adults. Although steroids remain a corner-
stone of therapy in JDM and are useful in many cases of CIDP and JMG, other immunomod-
ulatory therapies with similar efficacy maybeusedmorefrequently in some children to avoid
these long-term sequelae. Steroids are less expensive than most other therapies, but chronic
steroid therapy in childhood may lead to significant and costly medical complications. An-
otherexampleisplasmaexchange.Thistreatmentmodalitypresentschallengesinpediatrics,
asyoungerchildrenrequirecentral venousaccessforthis therapy. However, inolderchildren
andadolescents,plasmaexchangeisoftenfeasibleviaperipheralvenousaccess,makingthis
treatment more accessible than might be expected in this age group. Intravenous immuno-
globulin also is beneficial in several of these disorders, but its high cost may present barriers
to its use in the future. Newer steroid-sparing immunomodulatory agents, such as azathio-
prine, tacrolimus, mycophenolate mofetil, and rituximab, have not been studied extensively
in children. They show promising results from case reports and retrospective cohort studies,
but there is a need for comparative studies looking at their relative efficacy, tolerability, and
long-term adverse effects (including secondary malignancy) in children.
Introduction
Childhood autoimmune neuromuscular diseases are
a heterogeneous group of acquired inflammatory
disorders that result from autoimmune sensitiza-
tion. The most common ones include Guillain-
Barré syndrome, chronic inflammatory demyelinat-
ing polyradiculoneuropathy (CIDP), juvenile myas-thenia gravis, and juvenile dermatomyositis. Others,
such as vasculitic neuropathies, Lambert-Eaton my-
asthenic syndrome, polymyositis, and overlap myo-
sitis, have been reported in children but are rare in
this age group.
These diseases share some common elements of
immune dysregulation, namely T-cell activation with
subsequent antibody and complement deposition in
nerve, neuromuscular junction, or muscle (Table 1).
Postinfectious molecular mimicry and genetic predis-
positions have been proposed for some autoimmune
disorders, although mechanistic details remain un-
clear. Treatment of childhood autoimmune disorders
is based upon published prospective and retrospective
cohort studies, expert opinion, pediatric randomized
controlled trials (particularly for Guillain-Barré syn-
drome and dermatomyositis), and extrapolation of
results from adult studies. Early diagnosis and initia-
tion of treatment can significantly reduce long-term
morbidity for these diseases.
Outcome is often good when aggressive and appro-
priate therapies are used to treat these disorders, but
some of the treatments used have not been studied
as rigorously in children as in adults. Further prospec-
tive studies of therapies for these diseases in childhood
are needed.
Treatment
Guillain-Barré syndrome
& Guillain-Barré syndrome (GBS) results from a loss of immunologic
tolerance wherein autoreactive T lymphocytes, antibodies, and
complement damage myelinated peripheral nerves [1]. Two thirds of
GBS patients have an antecedent infection in the month prior to
onset, fueling the theory of postinfectious molecular mimicry as the
basic pathophysiologic mechanism [2]. GBS is uncommon in the
first few years of life, but rare cases of neonatal GBS have been
reported [3]. GBS is divided into several clinical subgroups: acute
inflammatory demyelinating polyradiculoneuropathy (AIDP), Miller-
Table 1. Antibodies in autoimmune neuromuscular disorders of childhood
Disorder Antibody
a
Neuromuscular junction
Juvenile myasthenia gravis (JMG) Anti-AChR, anti-MuSK, anti-striated muscle
Lambert-Eaton myasthenic syndrome (LEMS) Anti-VGCC
Muscle
Dermatomyositis, polymyositis Myositis-specific antibodies
Anti-Jo1, anti-p155, anti-p140
Anti-nuclear antibody (ANA)
Nerve
Guillain-Barré syndrome
Acute inflammatory demyelinating polyneuropathy (AIDP) None known
Acute motor axonal neuropathy (AMAN) Anti-GM1
Miller-Fisher variant Anti-GQ1b
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) Anti-MAG (rare)
aPositive antibody titers are not always identified in patients with these disorders, so the sensitivity of the specific titer should be con-
sidered when interpreting such results
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Treatment is similar for all forms of GBS.
& Pediatric and adult GBS patients present with progressive, symmetrical
muscle weakness and diminished or absent deep tendon reflexes. Pain
is often a prominent symptom, particularly in younger children, with
50% to 80% complaining of severe back, buttock, or limb pain [4–6,
7￿￿]. Autonomic symptoms, including variability in heart rate, blood
pressure, and thermoregulation, occur in20% to40% ofchildren, with
respiratory failure seen in 16% to 17% [4, 5]. Both autonomic and
respiratory complications are less frequent in children than in adults.
Children presenting with symptoms suggestive of GBS require close
observation because of the possibility of rapidly progressive respiratory
weakness, bulbar dysfunction, or autonomic dysfunction.
& Diagnostic criteria are well established for GBS [8]. In recent years,
enhancement and thickening of the nerve roots on MRI imaging of
the spine have been used to support the diagnosis, but these findings
are not always specific to GBS [9￿]. The long-term outcome of
childhood GBS is quite favorable, though recovery is sometimes
prolonged in the AMAN subtype, compared with AIDP [10]. Young
age and rapid symptom progression may heighten the risk of long-
term sequelae, but even though over 20% of children experience
residual weakness, it rarely results in any functional impairment [4].
& Early treatment with intravenous immunoglobulin (IVIG) or plasma
exchange (PE) is recommended for any child with GBS who has
difficulty ambulating [11].
Intravenous immunoglobulin (IVIG)
Two small, randomized pediatric trials have demonstrated the efficacy of
early IVIG therapy versus placebo [12, Class II] and versus late IVIG treat-
ment[13, Class II].In each study, IVIG reduced the timebetween symptom
onset and the patients’ initial and complete recovery [12, 13]. A retrospec-
tive study also supports the use of IVIG in pediatric GBS [14, Class IV].
Standard dosage The total IVIG dose is typically 2 g/kg divided over 2 to 5 days.
Mechanism of action Multiple actions have been postulated. IVIG has been shown to neutralize
the blocking effects of some autoantibodies [15]. IVIG is also thought to
downregulate T-cell activity and antibody production.
Side effects Headache, nausea, vomiting, allergic reactions, and aseptic meningitis may
occur. IVIG must be used cautiously in children with cardiac or renal dys-
function. Renal failure has been described in rare cases.
Cost IVIG is very expensive.
Plasma exchange
PE, also known as plasmapheresis, is an accepted alternative to IVIG
therapy in GBS patients. PE appears as efficacious as IVIG in at least five
adult randomized controlled trials [16, Class I]. PE has also been shown to
improve patient strength and reduce duration of mechanical ventilation
more than placeboin adult GBS, although these studies were subject to less
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childhood GBS [17, Class III]. No pediatric randomized controlled trial has
studied the efficacy or tolerability of PE in this population. On the basis
of the strong evidence of equal efficacy of IVIG and PE for adult GBS
patients, either therapy can be offered to pediatric GBS patients. The choice
between the two treatments in a particular case may be influenced by
technical feasibility, side effect profile, and cost.
Mechanism of action PE is thought to wash out or remove autoantibodies and inflammatory
cytokines.
Main side effects Potential short-term side effects include hypotension, electrolyte imbalance,
or coagulopathy. Chronic PE frequently causes anemia, and it also may cause
hypocalcemia and hypogammaglobulinemia (with increased susceptibility
to infection) [18].
Corticosteroids and other immunosuppressive medications
Corticosteroids are not beneficial in the treatment of GBS [19, Class II].
Given the short, monophasic nature of GBS, there is no role for chronic
immunosuppressive medications.
Physical therapy and exercise
Physical therapy is essential in the rehabilitation of children with GBS.
This intervention can help a child regain skills during convalescence and
may also help prevent the formation of contractures.
Chronic inflammatory demyelinating polyradiculoneuropathy
& CIDP is distinguished from GBS by the chronic nature of the disease.
Children demonstrate either a progressive or relapsing sensorimotor
polyneuropathy and/or polyradiculopathy for at least 2 months [20].
Although many CIDP patients exhibit a slow, insidious onset of
weakness and sensory loss, up to 16% may exhibit an initial acute
onset that mimics GBS [21].
& CIDP diagnostic criteria are aimed at distinguishing the disorder
both from its acute-onset counterpart, GBS, and from hereditary and
metabolic neuropathies [20, 22, Class IV]. Diffuse nerve root thick-
ening and gadolinium enhancement on spine MRI were present in
60% of adult CIDP patients in one series [23]. These findings have
also been observed in childhood CIDP [24] and can strengthen di-
agnostic certainty when present, but it should be noted that similar
MRI findings may be seen in inherited neuropathies such as Charcot-
Marie-Tooth disease [25, Class IV].
& CIDP may be treated with IVIG, PE, or corticosteroids [26￿￿, Class I].
Diet and lifestyle
Adequate intake of vitamin D and calcium is essential for optimizing bone
health and reducing risk of osteoporosis. Recommendations for vitamin D
supplementation vary, but a dose of 800 to 1000 IU daily is reasonable.
Calcium intake should be optimized primarily from dietary sources.
Growth velocity and weight gain should be closely monitored, par-
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are relevant to all autoimmune neuromuscular disorders of childhood.
IVIG and PE
Several case series of childhood CIDP have reported IVIG and cortico-
steroids to be efficacious [24, 27–32, Class IV]. PE also appears to be
beneficial in some cases of childhood CIDP, though it is less frequently
used [24, 28, 31, 32, Class IV]
Numerous randomized trials of adult CIDP have shown IVIG to be
superior to placebo [33–37, Class I]. PE has also been demonstrated to
be superior to placebo in adult CIDP [38]. Other trials demonstrated
equal efficacy of IVIG versus PE [39, Class I] or corticosteroids [40, Class I].
Corticosteroids
Corticosteroids appear to be effective in adults [40, Class I] and children
[24, 27–29, 31, 32, Class IV] with CIDP.
Mechanism of action Corticosteroids exert a broad immunosuppressive effect; the function and
numbers of lymphocytes and monocytes are particularly affected [41].
Main side effects The numerous side effects of chronic corticosteroid therapy [42] are partic-
ularly detrimental to children who are at a critical stage of vertical growth
and bone mineral deposition. In rare cases, the initiation of steroids has been
linked to hip osteonecrosis. Potential complications from long-term corti-
costeroid therapy can include decreased linear growth velocity and reduction
of final adult height, bone demineralization, weight gain, acne, and behavior
problems. Hypertension, hyperglycemia, and cataracts may occur.
Special points Depending on the severity of the case and the expected duration of treat-
ment, a steroid-sparing drug (e.g., azathioprine) may be started simulta-
neously, with the goal of reducing the duration of steroid treatment.
Azathioprine
Azathioprine is the most widely used steroid-sparing therapy in child-
hood CIDP [27, Class IV]. One prospective cohort study of azathioprine
in adult CIDP failed to show any definite improvement when this
medication was added for patients receiving corticosteroids [43, Class II],
but this study may have been too short (9 months) to detect beneficial
effects.
Standard dosage A standard starting dose for azathioprine is 1 mg/kg per day given daily or di-
vided in two doses. The dose may be increased by 0.5 mg/kg per day every
4 weeks to a maximum of 2.5 mg/kg per day. Dose adjustments are needed in
renalfailureandthiopurinemethyltransferasedeficiency.Dosingbyweightmay
needtobelowerinobesepatientswhoweighmorethanthetypicaladult.Atrial
of 12 weeks is usually sufficient to determine therapeutic efficacy.
Mechanism of action Azathioprine antagonizes purine metabolism inhibiting DNA and RNA
replication.
Main side effects Side effects can include somnolence, bone marrow suppression, and revers-
ible hepatitis or pancreatitis. Surveillance blood testing is required. Female
patients should be counseled about possible teratogenic effects of this and
other immunosuppressants. There have been reports of malignancy associ-
ated with chronic azathioprine use [44, Class IV]. The US Food and Drug
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cell lymphoma in adolescents and young adults receiving this therapy. These
risks should be discussed with any patient before the initiation of treatment
and again during treatment. Alternative therapies should be discussed as
needed, especially when the duration of azathioprine use extends beyond a
year.
Other immunosuppressants
Cyclosporine (discussed below) offered some benefit in an adult CIDP
trial [45, Class III] and in a small series of children [46, Class IV].
Case reports and retrospective trials have looked at other immuno-
suppressant medications, but data pertaining to their efficacy in children
is sparse.
Physical therapy and exercise
Physical therapy is an important component of the long-term man-
agement of CIDP. This intervention may help children, especially in
the recovery phase of exacerbations, and also may help to prevent
contractures.
Juvenile myasthenia gravis
& Patients with juvenile myasthenia gravis (JMG) can be offered three
main categories of disease-modifying therapy: acetylcholinesterase
inhibitors (AChE-I), medical immunomodulation or immunosup-
pression, and surgical intervention (thymectomy).
Diagnosis
& JMG is an autoimmune disorder resulting from antibodies directed at
neuromuscular junction proteins, most commonly acetylcholine
receptors (AChR). Children develop symptoms of muscle fatigability
due to impaired neuromuscular transmission. Prepubertal patients
often present with isolated oculomotor symptoms, including diplo-
pia and ptosis [47, Class IV]. Some children go on to develop gen-
eralized weakness, though this appears to occur less frequently than
in post-pubertal patients. No clear gender predominance exists in
prepubertal JMG patients [48, Class IV], but a female preponderance
emerges after puberty [49, 50, Class IV]. JMG can present at any age
but is less common during infancy. In infants and toddlers, JMG may
be difficult to differentiate from transient neonatal myasthenia gravis
and congenital myasthenic syndrome.
& Although the diagnosis of JMG is based primarily upon the clinical
presentation,supportivedataincludethepresenceofserumantibodies,
edrophonium testing, and abnormal electrodiagnostic testing (repeti-
tive nerve stimulation and single-fiber electromyography [EMG]).
& Whereas antibodies to the nicotinic AChR are found in 80% of adults
with myasthenia gravis [51], only 50% of prepubertal and 70% of
peripubertal JMG patients have anti-AChR antibodies [49, 52, Class
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muscle have been reported in children but are rare in JMG, and the
cost of anti-MuSK titers is often higher than that of AChR antibody
titers [53￿, 54].
& Edrophonium testing involves the use of a short-acting AChE-I.
Dosing in infants should be discussed with a neurologist experienced
with performing the test in this age group. Children older than 1 year
who weigh less than 34 kg are treated with an edrophonium test dose
of 0.5 mg, followed by 1-mg increments to a maximum total dose of
5 mg. Children weighing 34 kg or more are treated with the adult
edrophonium dose, a 0.5-mg test dose followed by increments of 1
to 2 mg until a maximum dose of 10 mg is attained. In addition to
clinical monitoring, preinjection and postinjection photos, taken
with the consent of the patient and/or family, may be helpful. Be-
cause of the risk of symptomatic bradycardia, asystole, and hypo-
tension, testing must be performed in a monitored setting with staff
trained in cardiac resuscitation. Some patients with congenital my-
asthenic syndrome may deteriorate with exposure to an AChE-I (e.g.,
COLQ mutation or AChR slow channel mutation). Positive edro-
phonium testing is not specific for JMG and can be seen with other
disorders of neuromuscular transmission. Lambert-Eaton myasthenic
syndrome (LEMS) has been reported in children but is exceedingly
rare in this age group [55].
& Young children may require sedation to facilitate repetitive stimula-
tion and stimulated single-fiber EMG.
Diet and lifestyle
Adequate intake of vitamin D and calcium is essential for optimizing bone
health and reducing risk of osteoporosis. Recommendations for vitamin D
supplementation vary, but a dose of 800 to 1000 IU daily is reasonable. Cal-
cium intake should be optimized primarily from dietary sources.
Growth velocity and weight gain should be closely monitored, partic-
ularly in children receiving corticosteroids.
Pharmacologic therapy
Pyridostigmine
Pyridostigmine bromide is standard first-line JMG therapy.
Standard dosage Initial oral dosing is 0.5 to 1 mg/kg per dose (maximum 60 mg) every 4 to
6 h while awake. Onset of effect occurs rapidly (within 15–30 min) and
duration is up to 3 to 4 h. For young children, regular tablets may be crushed
or the liquid form (60 mg/5 mL) can be used. The maximum daily dose is
7 mg/kg per day or 300 mg/day. In rare cases, higher doses may be used, but
only if prescribed by a neurologist experienced with this medication. The
596 Pediatric Neurology (Harvey Singer, Section Editor)intravenous form of pyridostigmine requires a significant dose adjustment,
so it should be used with caution, if at all.
Drug interactions Pyridostigmine may increase the effects of depolarizing neuromuscular block-
ing drugs (e.g., succinylcholine, aminoglycosides) and β-blockers. Corticoste-
roids may lessen the effects of pyridostigmine. Atropine is an antagonist.
Main side effects Muscarinic (cholinergic) effects (e.g., cramping, diarrhea, salivation) may limit
dosing insomechildren.Overdosage may precipitate a cholinergic crisis,which
can be difficult to distinguish from a myasthenic crisis except for superimposed
muscarinic symptoms, which may not be obvious in every patient.
Intravenous immunoglobulin
IVIG is commonly used to treat acute JMG exacerbations and also is used
as chronic maintenance therapy for some patients. Data pertaining to
IVIG efficacy in myasthenia gravis (MG) is based largely on data from
adult randomized placebo-control trials [56, Class I].
Standard dosage AcuteJMGexacerbationsaretreatedwith2g/kgofIVIG,dividedover2to5days
[53￿]. The precise dose of IVIG remains unclear, with an adult study docu-
menting no short-term difference in efficacy between 1 g/kg versus 2 g/kg [57,
ClassI].Anecdotally, some patientscan bemaintainedon chronic IVIGtherapy
(typically1g/kgeveryfewweeks,withtheexactintervaldependingonseverity),
but there are no randomized studies supporting this approach [58].
Mechanism of action Multiple actions have been postulated. IVIG has been shown to neutralize
the blocking effects of some autoantibodies [15]. IVIG is also thought to
downregulate T-cell activity and antibody production.
Side effects Headache, nausea, vomiting, allergic reactions, and aseptic meningitis may
occur. IVIG must be used cautiously in children with cardiac or renal dys-
function. Renal failure has been described in rare cases.
Cost IVIG is very expensive.
Corticosteroids
Corticosteroids (prednisone, prednisolone, methylprednisolone) are ef-
fective immunosuppressants with good evidence for their efficacy in MG
[59, Class II]. Steroid therapy is a traditional choice for MG patients re-
quiring long-term immunosuppression [60￿, Class IV]. Several studies
have demonstrated a beneficial response in more than 70% of adult MG
patients [61–64; Class IV].
Standard dosage Caution must be taken when initiating therapy, as increased weakness may
occur within the first 1 to 2 weeks of treatment, potentially precipitating a
myasthenic crisis [61]. To minimize this risk, outpatient corticosteroid
therapy should be started at a low dose (typically 0.5 mg/kg per day; maxi-
mum 30 mg/day) and gradually increased at weekly increments until an
effect is observed [53￿]. Severely ill patients who are admitted to the hospital
may start at higher doses (intravenous methylprednisolone 2 mg/kg per day,
with a maximum of 60–80 mg/day), but they need to be observed in the
hospital for at least a week after initiation [53￿].
Mechanism of action Corticosteroids exert a broad immunosuppressive effect; the function and
numbers of lymphocytes and monocytes are particularly affected [41].
Main side effects The numerous side effects of chronic corticosteroid therapy [42]a r e
particularly detrimental to children who are at a critical stage of vertical
growth and bone mineral deposition. In rare cases, the initiation of
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from long-term corticosteroid therapy can include decreased linear
growth velocity and reduction of final adult height, bone demineraliza-
tion, weight gain, acne, and behavior problems. Hypertension, hyper-
glycemia, and cataracts may occur.
Special points Depending on the severity of the case and the expected duration of treat-
ment, a steroid-sparing drug (e.g., azathioprine) may be started simulta-
neously, with the goal of reducing the duration of steroid treatment.
Cost Steroids are inexpensive, but they may cause significant and costly long-term
side effects when used on a chronic basis.
Azathioprine
Azathioprine is commonly used as a steroid-sparing immunosup-
pressant agent in adult MG [65,C l a s sI V ]a n dJ M G[ 48, 50, 53￿,
Class IV]. Although randomized trials in adult MG patients have not
found azathioprine to improve clinical strength scores [66,C l a s sI ] ,i t
has been shown to be associated with lower corticosteroid dosing
during long-term use by patients with chronic MG [67,C l a s sI ] .
Dosage and side effects are similar to those in patients with CIDP, as
discussed above.
Cyclosporine
Cyclosporine, also classified as a steroid-sparing immunosuppressant,
has proven beneficial in adult MG [68, Class I; 69, 70, Class III], and its
use has been reported in some JMG patients [50, Class IV].
Standard dosage Dosing of cyclosporine for JMG has not been established, but the dosing
guidelines for inflammatory diseases may be a useful guide. These suggest a
starting dose of 2.5 mg/kg per day divided in two doses. At 8 and 12 weeks of
therapy,thedosemaybeincreasedby0.5to0.75mg/kgperday.Themaximum
doseis4mg/kgperday.Thedosagemayneedtobeadjustedforrenalorhepatic
impairment. Different brands of cyclosporine are not bioequivalent, so each
patient must stay on the same brand for the duration of therapy. Checking se-
rum levels and monitoring for signs of end-organ toxicity are essential. Neu-
rologists not experienced in the use of cyclosporine in children should consult
with a colleague who has such experience before initiating therapy.
Mechanism of action Cyclosporine inhibits the production and release of interleukin 2, thereby
inhibiting T-cell activation.
Main side effects Adverse effects may include abdominal pain, nausea, diarrhea, hepatitis,
bone marrow suppression, hirsutism, and gingival hyperplasia. Serious po-
tential effects include nephrotoxicity (often manifesting as hypertension),
malignancy, and infections. Seizures infrequently occur (particularly if re-
ceiving concomitant high-dose corticosteroids). These side effects must be
discussed with patients and their families before initiation of treatment.
Breast-feeding is contraindicated during therapy.
Drug interactions Cyclosporine is metabolized via the cytochrome P450 pathway, giving rise to
many potential drug interactions.
Tacrolimus
Tacrolimus therapy appeared promising in one small, unblinded, ran-
domized trial [71, Class II] and one nonrandomized trial in adult MG
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diseases such as severe atopic dermatitis and in children who have
received solid-organ transplants. There are no data pertaining to the
use of this drug in JMG, so a physician experienced in its use should
be consulted prior to the initiation of therapy. Blood testing is re-
quired to determine therapeutic levels and monitor for signs of end-
organ toxicity.
Mechanism of action Tacrolimus affects intracellular calcineurin, inhibiting T-cell activation.
Main side effects Adverse effects can include nausea, diarrhea, bone marrow suppression,
hypertension (nephrotoxicity), neurotoxicity (encephalopathy, polyneurop-
athy), ototoxicity, and increased risk of malignancy.
Drug interactions Concomitant use with other immunosuppressants can increase risk of in-
fection and secondary malignancy. Concomitant use with cyclosporine may
increase the risk of nephrotoxicity. Tacrolimus is metabolized via the cyto-
chrome P450 pathway, giving rise to many potential drug interactions.
Grapefruit may increase the serum tacrolimus concentration.
Other immunosuppressants
Methotrexate is often used as an alternative immunosuppressant agent in
adults with MG who are unable to tolerate azathioprine, although very
little published evidence supports the use of this drug in MG. The proven
efficacy of methotrexate for other autoimmune diseases (such as der-
matomyositis, discussed below) is used as the main argument for the use
of this drug in MG.
Cyclophosphamide therapy has been used for severe, treatment-re-
sistant adult MG [65, Class IV].
Rituximab has been used with promising results in adults with severe,
refractory MG [73, Class IV], although the efficacy of this drug in JMG is
unclear.
There are a number of anecdotal reports of the efficacy of mycophe-
nolate mofetil in adult MG, but a large randomized controlled trial in
adults failed to show a clear benefit [74, Class I]. Thus its role in MG
therapy is unclear at this time.
Plasma exchange
& PE is an alternative to IVIG for treating acute exacerbations [18, Class
I] (typically with five exchanges performed on alternate days) or
chronic JMG (typically one exchange every few weeks) [53￿], al-
though no randomized trials support the long-term use of PE in this
population. IVIG and PE show equal short-term efficacy in treating
exacerbations of adult MG [18, Class I; 75￿, Class I]. PE also has been
shown to be beneficial when administered to adults with MG prior
to thymectomy, reducing the duration of postoperative mechanical
ventilation [76￿, Class II].
& Potential short-term side effects of PE include hypotension, electro-
lyte imbalance, or coagulopathy. Chronic PE frequently causes ane-
mia, and it also may cause hypocalcemia and
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[18].
Surgical therapy
& Thymectomy is often performed in patients with generalized MG, in-
cluding children. The presence of a thymoma is an absolute indication
forthymectomy.Basedonretrospectivedata, thymectomy also appears
to be beneficial for nonthymomatous generalized JMG, with almost
70% of patients improving after thymectomy and 40% exhibiting
complete remission, including discontinuation of medication [77￿￿,
Class III]. These outcomes are better than the overall spontaneous re-
missionrateof14%to30%inJMG[78,79,ClassIV].Tworetrospective
studies also report an association between early thymectomy and like-
lihood of remission in JMG [77￿￿, 78, Class IV]. These studies support
theroleofthymectomyasatherapyforJMG.Prospectivedatawouldbe
helpful, but conducting such a study would be difficult.
Physical therapy and exercise
& MG is one of the only neuromuscular disorders in which physical
therapy and exercise should be used with caution. Excessive physical
activity will often trigger worsening of symptoms. Physical therapy
should be initiated only upon the recommendation of the treating
neurologist, and is usually most helpful in the later stages of recovery
or in the postoperative period after thymectomy. Light to moderate
exercise is often beneficial, but only as tolerated by the patient.
Dermatomyositis
& Juvenile dermatomyositis (JDM) accounts for at least 85% of in-
flammatory myopathies in childhood [80]. JDM is a systemic disease
resulting from desensitization of lymphocytes with subsequent
damage mediated by autoantibodies and complement.
& Immunosuppressant therapy is the mainstay of JDM treatment and
has brought about a marked improvement in long-term outcome
with the advent of early and consistent treatment [81]. Mortality
from JDM has decreased from 25% [81] to less than 2% [82]. Mor-
bidity has also lessened, with one follow-up study reporting mod-
erate to severe disability in less than 10% of children [82]. Treatment
strategies in JDM are based on small, retrospective studies and expert
opinion. There are no randomized controlled trials pertaining to
JDM treatment.
Diagnosis
& Classically, the diagnostic criteria for dermatomyositis require
patients to have a characteristic skin rash as well as any three of the
following four additional features: symmetrical proximal muscle
weakness, raised muscle enzyme levels, perifascicular atrophy on
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will present with involvement of skin (90%) and/or muscle (980%)
[80, 84]. EMG is now performed for the diagnostic evaluation of
dermatomyositis than less often than in the past, but it may be useful
in cases of atypical presentations. Muscle MRI is a relatively new
diagnostic tool that is becoming increasingly popular.
& Common muscle symptoms include myalgia and symmetrical
weakness of the neck and hip flexors. When weakness precedes the
characteristic skin findings, it may be difficult to distinguish JDM
from other inflammatory myopathies (i.e., polymyositis, overlap
myositis) or even some forms of muscular dystrophy.
& The characteristic skin findings of JDM include the heliotrope rash
and Gottron papules (seen in 75% of patients) [84]. Other skin
findings include malar rash, periungual telangiectasia, mouth ulcers,
skin ulceration, and calcinosis.
& Organ systems less commonly involved include lungs (interstitial
lung disease), gut (gastrointestinal bleeding), joints (arthralgia),
heart (myocarditis), and eyes (cataracts).
& JDM is associated with autoantibodies in about 40% to 50% of cases
[85, 86￿]. Myositis-specific autoantibodies such as anti-Jo-1, anti-
p155, and anti-p140 are the most common autoantibodies seen in
JDM [86￿]. An elevation of antinuclear antibodies (ANA), serum
creatine kinase (CK), or erythrocyte sedimentation rate (ESR) is also
found in many, though not all, children with active JDM [87].
& Adult dermatomyositis is typically associated with malignancy, but
this is rare in JDM, and screening for occult malignancy is not nec-
essary unless clinical suspicion exists [85, Class IV].
Diet and lifestyle
Adequate intake of vitamin D and calcium is essential for optimizing bone
health and reducing risk of osteoporosis. Recommendations for vitamin D
supplementation vary, but a dose of 800 to 1000 IU daily is reasonable. Cal-
cium intake should be optimized primarily from dietary sources.
Growth velocity and weight gain should be closely monitored, particular-
ly in children receiving corticosteroids.
Pharmacologic therapy
Corticosteroids
Corticosteroids are used by most clinicians in the treatment of JDM. A
recent North American practice survey of pediatric rheumatologists
revealed that clinicians treat mild JDM with corticosteroid monotherapy
(G10% of cases); combination corticosteroid and methotrexate (40%), or
corticosteroid, methotrexate, and hydrochloroquine (35%). Severe JDM
was often treated with combined corticosteroid, methotrexate, and IVIG
therapy or corticosteroids and cyclophosphamide [88￿, Class IV].
Autoimmune Neuromuscular Disorders in Childhood McMillan et al. 601Standard dosage Therapy may begin with either high-dose oral prednisone (2 mg/kg per day,
maximum 60–80 mg/day) or pulse intravenous methylprednisolone (20–
30 mg/kg per day, maximum 1 g/day for 5 days) In either case, daily oral
prednisone is then continued at 2 mg/kg per day (maximum 60–80 mg/day)
for 4 weeks before gradual tapering [89￿￿, Class IV]. Early and aggressive
corticosteroid therapy is associated with better disease outcome [90, Class IV].
Main side effects The numerous side effects of chronic corticosteroid therapy [42] are partic-
ularly detrimental to children who are at a critical stage of vertical growth
and bone mineral deposition. In rare cases the initiation of steroids has been
linked to hip osteonecrosis. Potential complications from long-term corti-
costeroid therapy can include decreased linear growth velocity and reduction
of final adult height, bone demineralization, weight gain, acne, and behavior
problems. Hypertension, hyperglycemia, and cataracts may occur.
Methotrexate
Combination therapy using methotrexate and a corticosteroid has been
shown to improve long-term outcome and reduce corticosteroid-related
side effects in JDM. [91, 92, Class II].
Mechanism of action Methotrexate is a dihydrofolate reductase inhibitor, which causes depletion
of folic acid and depletion of DNA precursors.
Main side effects Adverse effects can include nausea, diarrhea, bone marrow suppression, al-
opecia, rash, cystitis, hepatitis, and nephropathy. Female patients should be
counseled about the risk of teratogenicity.
Drug interactions Penicillin and aspirin may increase methotrexate levels.
Hydroxychloroquine
Hydroxychloroquine has also been used as a successful adjunct therapy
for JDM [93, Class III] and is often started concomitantly with cortico-
steroids and methotrexate, particularly in mild JDM [88￿].
Mechanism of action Hydroxychloroquine interferes with leukocyte chemotaxis and complement-
dependent antigen–antibody reactions.
Main side effects Adverse effects can include nausea, diarrhea, bone marrow suppression,
psychiatric symptoms, rash, photosensitivity, and hepatotoxicity.
Other immunosuppressants
Severe or refractory JDM has been treated with IVIG [94,C l a s sI V ] ,
cyclosporine [95,C l a s sI V ;96, Class III], cyclophosphamide [97,
Class IV], mycophenolate mofetil [98, Class IV], tacrolimus [99,C l a s s
IV], and rituximab [100, Class IV]. One small retrospective study has
suggested that certain JDM patients may do well with IVIG and/or
methotrexate therapy alone (i.e., no corticosteroids) [101￿,C l a s sI V ] ,
but this study must be interpreted with caution, particularly as cor-
ticosteroid therapy is accepted as the standard of care by most
physicians [88￿].
Physical therapy and exercise
& Physical therapy and exercise willoften be helpful inJDM,but the level
of potential activity may be limited when the weakness is severe.
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